Combinational Inhibition of MEK and AKT Synergistically Induces Melanoma Stem Cell Apoptosis and Blocks NRAS Tumor Growth
Cells · 2025
DOI: 10.3390/cells14040248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Ryyan Alobaidi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC 20057, USA. Hauptthemen laut MEDLINE: Apoptosis, Melanoma, Proto-Oncogene Proteins c-akt, Neoplastic Stem Cells. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIEHS, NIH, NIEHS NIH HHS.
Abstract (Originalsprache)
Malignant melanoma is a lethal skin cancer containing melanoma-initiating cells (MICs), implicated in tumorigenesis, invasion, and drug resistance, and characterized by an elevated expression of stem cell markers, including CD133. siRNA knockdown of CD133 has been previously shown to enhance apoptosis induced by the MEK inhibitor trametinib in melanoma cells. This study investigates the underlying mechanisms of CD133’s anti-apoptotic activity in patient-derived BAKP melanoma, harboring the difficult-to-treat NRASQ61K driver mutation, after CRISPR-Cas9 CD133 knockout or Doxycycline (Dox)-inducible re-expression of CD133. CD133 knockout in BAKP cells increased trametinib-induced apoptosis by reducing anti-apoptotic p-AKT and p-BAD and increasing pro-apoptotic BAX. Conversely, Dox-induced CD133 expression diminished apoptosis in trametinib-treated cells, coincident with elevated p-AKT, p-BAD, and decreased activation of BAX and caspase-3. However, trametinib in combination with pan-AKT inhibitor capivasertib reduced cell survival as measured by XTT viability assays and apoptosis and colony formation assays, independent of CD133 status. CD133 may therefore activate a survival pathway wherein (1) increased AKT phosphorylation and activation induces (2) BAD phosphorylation and inactivation, which (3) decreases BAX activation, and (4) reduces caspases-3 activity and caspase-mediated PARP cleavage, leading to apoptosis suppression and drug resistance in melanoma. In vivo mouse xenograft studies using Dox-inducible melanoma cells revealed increased rates of tumor growth after induction of CD133 expression in trametinib-treated +Dox mice, an effect which was synergistically suppressed by combination treatment. Targeting nodes of the AKT and MAPK survival pathways with trametinib and capivasertib highlights the potential for combination therapies for NRAS-mutant melanoma stem cells for the development of more effective treatments for patients with high-risk melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC 20057, USA.
- Department of Pathology, King Saud University College of Medicine, Riyadh 11461, Saudi Arabia.
- Amelia Technologies, LLC, Washington, DC 20001, USA.
ORCID-Profile: Ryyan Alobaidi, Nusrat Islam, Yogameenakshi Haribabu, Peter Sykora, Cynthia M Simbulan-Rosenthal, Dean S Rosenthal
Förderung
- NIGMS NIH HHS
- NIEHS, NIH
- NIEHS NIH HHS
- NIEHS NIH
- NIGMS NIH
Zitieren
APA
Alobaidi, R., Islam, N., Olkey, T., Haribabu, Y., Shamo, M., Sykora, P., Simbulan-Rosenthal, C. M., & Rosenthal, D. S. (2025). Combinational Inhibition of MEK and AKT Synergistically Induces Melanoma Stem Cell Apoptosis and Blocks NRAS Tumor Growth. Cells. https://doi.org/10.3390/cells14040248
Vancouver
Alobaidi R, Islam N, Olkey T, Haribabu Y, Shamo M, Sykora P, et al. Combinational Inhibition of MEK and AKT Synergistically Induces Melanoma Stem Cell Apoptosis and Blocks NRAS Tumor Growth. Cells. 2025. doi:10.3390/cells14040248
BibTeX
@article{Alobaidi2025,
author = {Alobaidi, Ryyan and Islam, Nusrat and Olkey, Toni and Haribabu, Yogameenakshi and Shamo, Mathew and Sykora, Peter and Simbulan-Rosenthal, Cynthia M and Rosenthal, Dean S},
title = {Combinational Inhibition of MEK and AKT Synergistically Induces Melanoma Stem Cell Apoptosis and Blocks NRAS Tumor Growth},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14040248}
}
EUVIMED